Anatole Besarab

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Anatole Besarab, W. Kline Bolton, Joan C. Egrie et al. · New England Journal of Medicine · 1998 · 1.9K citations · Full text

Medicine, Nephrology, Pharmacotherapy +16

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Iain C. Macdougall, Andreas J. Bircher, Kai‐Uwe Eckardt et al. · Kidney International · 2016 · 475 citations · Full text

Medicine, Hematology, Nephrology +17

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Robert Provenzano, Anatole Besarab, Chao Sun et al. · Clinical Journal of the American Society of Nephrology · 2016 · 293 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis

Anatole Besarab, Kevin L. Sullivan, Richard P. Ross et al. · Kidney International · 1995 · 279 citations

Medicine, Surgery, Hemodynamic Management +13

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Anatole Besarab, Robert Provenzano, Joachim Hertel et al. · Nephrology Dialysis Transplantation · 2015 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13